PDCD1 and neoplasm: Winograd et al. reported a triple combination of gemcitabine/nab-paclitaxel with anti-PD-1 and immunostimulatory anti-CD40 mAbs using a genetically engineered mouse model of PDAC, resulting in an improved median overall survival of tumor-bearing mice [218].